Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-14

if it's your opinion that a change in management will undermine the company it's an option. My opinion would be that the management has undermined the shareholders for a few years, before I bought in. There was a pretty shady capital raise last year with the build up of Beckman Coulters marketing agreement. The FDA MRSA took an incredibly long time. There's directors on the board with no on market share holdings which doesn't exactly scream confidence in the company, not good for the market.

a fresh start with a fresh management might be the best option, having a new CEO and directors could help change the sales strategy LBT currently has, so far it takes a few months to organise a placement of a machine then 12 months to turn that placement to a sale. A new board with fresh eyes could find ways to improve that process